{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T09:28:49Z","timestamp":1765704529829,"version":"3.45.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception: X"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/j.conx.2020.100018","type":"journal-article","created":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T02:36:08Z","timestamp":1578969368000},"page":"100018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Combined hormonal contraceptive use in Europe before and after the European Commission mandated changes in product information"],"prefix":"10.1016","volume":"2","author":[{"given":"Deeksha","family":"Khialani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Elizabeth","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szimonetta Komj\u00e1thin\u00e9","family":"Sz\u00e9pligeti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Gulbech","family":"Ording","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Ehrenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"van Hylckama Vlieg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.conx.2020.100018_bb0005","first-page":"339","article-title":"Hormonal contraception and risk of venous thromboembolism: national follow-up study","volume":"b2890","author":"Lidegaard","year":"2009","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.conx.2020.100018_bb0010","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1600-0412.2012.01444.x","article-title":"Hormonal contraception and venous thromboembolism","volume":"91","author":"Lidegaard","year":"2012","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.conx.2020.100018_bb0015","first-page":"339","article-title":"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study","volume":"b2921","author":"van Hylckama Vlieg","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.conx.2020.100018_bb0020","first-page":"347","article-title":"Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis","volume":"f5298","author":"Stegeman","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.conx.2020.100018_bb0025","first-page":"343","article-title":"Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9","volume":"d6423","author":"Lidegaard","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.conx.2020.100018_bb0030","doi-asserted-by":"crossref","first-page":"h2135","DOI":"10.1136\/bmj.h2135","article-title":"Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases","volume":"350","author":"Vinogradova","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.conx.2020.100018_bb0035","series-title":"Availableat","article-title":"Benefits of combined hormonal contraceptives (CHCs) continue to outweigh risks \u2013 CHMP endorses PRAC recommendation. EMA\/709120\/2013","author":"European Medicines Agency","year":"2013"},{"issue":"3","key":"10.1016\/j.conx.2020.100018_bb0040","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/jfprhc-2013-100624","article-title":"Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism","volume":"39","author":"Bitzer","year":"2013","journal-title":"J Fam Plann Reprod Health Care"},{"issue":"4","key":"10.1016\/j.conx.2020.100018_bb0045","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.contraception.2016.06.010","article-title":"Impact of estrogen type on cardiovascular safety of combined oral contraceptives","volume":"94","author":"Dinger","year":"2016","journal-title":"Contraception"},{"issue":"9","key":"10.1016\/j.conx.2020.100018_bb0050","first-page":"75","article-title":"Venous thrombosis and hormonal contraception: what\u2019s new with estradiol-based hormonal contraceptives?. Open access","volume":"8","author":"Fruzzetti","year":"2018","journal-title":"J Contracept"},{"issue":"3","key":"10.1016\/j.conx.2020.100018_bb0055","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1160\/TH10-05-0327","article-title":"Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate\/17\u03b2-estradiol, compared with those of levonorgestrel\/ethinyl estradiol. A double-blind, randomised study","volume":"105","author":"Gaussem","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.conx.2020.100018_bb0060","unstructured":"Stichting Farmaceutische Kengetallen. Available at: https:\/\/www.sfk.nl\/english"},{"issue":"12","key":"10.1016\/j.conx.2020.100018_bb0065","first-page":"652","article-title":"NHG-Standaard Anticonceptie","volume":"54","author":"Brand","year":"2011","journal-title":"Huisarts Wet"},{"author":"Update","key":"10.1016\/j.conx.2020.100018_bb0070"},{"key":"10.1016\/j.conx.2020.100018_bb0075","unstructured":"Danish Medicines Agency (2016) P-pille analyse. Available at: https:\/\/laegemiddelstyrelsen.dk\/da\/udgivelser\/2016\/~\/media\/CD29697BD25C46 42968D9386979472A9.ashx"},{"issue":"4","key":"10.1016\/j.conx.2020.100018_bb0080","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/jfprhc-2015-101202","article-title":"Prescribing patterns of combined hormonal products containing cyproterone acetate, levonorgestrel and drospirenone in the UK","volume":"42","author":"Cea-Soriano","year":"2016","journal-title":"J Fam Plann Reprod Health Care"},{"key":"10.1016\/j.conx.2020.100018_bb0085","unstructured":"Central Bureau of Statistics. Available at: https:\/\/www.cbs.nl\/en-gb\/news\/2014\/25\/fewer-women-on-the-pill-iuds-more-popular"},{"key":"10.1016\/j.conx.2020.100018_bb0090","unstructured":"Sexual and Reproductive Health Services, England - 2017\u201318: Main report. Available at: https:\/\/files.digital.nhs.uk\/3A\/1D0442\/srh-serv-eng-17-18-rep.pdf"}],"container-title":["Contraception: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590151620300010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590151620300010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:35:05Z","timestamp":1762914905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590151620300010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":18,"alternative-id":["S2590151620300010"],"URL":"https:\/\/doi.org\/10.1016\/j.conx.2020.100018","relation":{},"ISSN":["2590-1516"],"issn-type":[{"type":"print","value":"2590-1516"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined hormonal contraceptive use in Europe before and after the European Commission mandated changes in product information","name":"articletitle","label":"Article Title"},{"value":"Contraception: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conx.2020.100018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100018"}}